Evaluation of risk factors for invasive fungal infection after allogeneic stem cell transplantation in pediatric patients

Journal of Pediatric Hematology/Oncology

Volumn 29, Issue 11, 2007, Pages 786-791

  Kobayashi, Ryoji ^a,b   Kaneda, Makoto ^a   Sato, Tomonobu ^a,b   Suzuki, Daisuke ^a   Ichikawa, Mizuho ^a   Ariga, Tadashi ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SAPPORO HOKUYU HOSPITAL   (Japan)

Author keywords

GVHD; Invasive fungal infection; Stem cell transplantation

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN A; FLUCONAZOLE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; ITRACONAZOLE; METHOTREXATE; METHYLPREDNISOLONE; MICAFUNGIN; MICONAZOLE; TACROLIMUS; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; COMBINATION CHEMOTHERAPY; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; DRUG EFFICACY; EVALUATION; FEMALE; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; HUNTER SYNDROME; HURLER SCHEIE SYNDROME; HURLER SYNDROME; HYPERIMMUNOGLOBULINEMIA M; INCIDENCE; JUVENILE MYELOMONOCYTIC LEUKEMIA; KOSTMANN SYNDROME; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MULTIVARIATE ANALYSIS; MYCOSIS; MYELODYSPLASTIC SYNDROME; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RECURRENT DISEASE; RHABDOMYOSARCOMA; RISK FACTOR; STATISTICAL SIGNIFICANCE; T CELL LEUKEMIA; UNIVARIATE ANALYSIS; VIRUS INFECTION; WISKOTT ALDRICH SYNDROME;

ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INCIDENCE; INFANT; JAPAN; MALE; MYCOSES; RISK FACTORS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 36048997322     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e318142b598     Document Type: Article

References (16)

1. Gold JW. Opportunistic fungal infections in patients with neoplastic disease. Am J Med. 1984;76:458-463.
2. Chandrasekar PH, Weinmann A, Shearer C. Autopsy identified infections among bone marrow transplant recipients: a clinicopathologic study of 56 patients. Bone Marrow Transplant. 1995;16:676-681.
3. Donnelly JP. Symptoms and diagnosis of nosocomial fungal infections - state-of-the-art. Eur J Med Res. 2003;7:192-199.
4. Erjavec Z, Verweij PE. Recent progress in the diagnosis of fungal infections in the immunocompromised host. Drug Resist Update. 2002;5:3-10.
5. Wald A, Leisenring W, van Burik JA, et al. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997;175:1459-1466.
6. Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100:4358-4366.
7. Hovi L, Saarinen-Pihkala UM, Vettenranta K, et al. Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years. Bone Marrow Transplant. 2000;26:999-1004.
8. Benjamin DK Jr, Miller WC, Bayliff S, et al. Infections diagnosed in the first year after pediatric stem cell transplantation. Pediatr Infect Dis J. 2002;21:227-234.
9. Dvorak CC, Steinbach WJ, Brown JM, et al. Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2005;36:621-629.
10. Ascioglu S, Rex JH, de Pauw B, et al., Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7-14.
11. van Burik JA, Ratanatharathorn V, Stepan DE, et al., National Institute of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39:1407-1416.
12. Glasmacher A, Prentice AG. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies. J Antimicrob Chemother. 2005;56(suppl 1):i23-i32.
13. van Burik JA, Weisdorf DJ. Infections in recipients of blood and marrow transplantation. Hematol Oncol Clin N Am. 1999;13:1065-1089.
14. Momin F, Chandrasekar PH. Antimicrobial prophylaxis in bone marrow transplantation. Ann Intern Med. 1995;123:205-215.
15. Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood. 2003;102:827-833.
16. Busca A, Saroglia EM, Giacchino M, et al. Analysis of early infectious complications in pediatric patients undergoing bone marrow transplantation. Support Care Cancer. 1999;7:253-259.